(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of 10.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Ptc Therapeutics's revenue in 2025 is $806,780,000.On average, 5 Wall Street analysts forecast PTCT's revenue for 2025 to be $73,158,673,671, with the lowest PTCT revenue forecast at $53,426,109,883, and the highest PTCT revenue forecast at $136,948,770,595. On average, 5 Wall Street analysts forecast PTCT's revenue for 2026 to be $70,321,348,157, with the lowest PTCT revenue forecast at $62,630,165,129, and the highest PTCT revenue forecast at $76,755,668,938.
In 2027, PTCT is forecast to generate $92,695,483,688 in revenue, with the lowest revenue forecast at $76,346,652,395 and the highest revenue forecast at $110,472,323,758.